Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Completed

• Conditions: Carcinoma, Renal Cell
• Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

• Registration Number: NCT01557127
• Lead Sponsor: Bayer

Brief Summary

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11-01
• Study First Submitted: 2012-03-16
• Study First Submitted QC: 2012-03-16
• Study First Posted: 2012-03-19
• Primary Completion: 2014-05-16
• Study Completion: 2016-03-31
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-24
• Last Update Posted: 2017-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 205

Inclusion Criteria

• Age >/= 18 years
• Diagnosis of renal cell carcinoma
• Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2
• Patients in whom the oncologist has decide to start therapy with sorafenib.

Read More

Exclusion Criteria

• Synonymous with contraindications to Nexavar.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1	Sorafenib (Nexavar, BAY43-9006)	-

Primary Outcome Measures

Name	Time	Method
Percentage of patients in whom the actual dose of sorafenib equaled the planned dose	12 months

Secondary Outcome Measures

Name	Time	Method
Overall tolerability of treatment as measured by rate of adverse events	12 months